New antibody drug conjugate enters first human trial for advanced cancers
NCT ID NCT05948826
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new drug called TORL-3-600 in 70 people with advanced solid tumors or colorectal cancer. The drug is an antibody drug conjugate designed to target and kill cancer cells. The main goals are to check safety, find the best dose, and see if it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TORL-3-600 (antibody drug conjugate)
What this could lead to
If successful, this could lead to a new treatment option for advanced cancers that have not responded to other therapies.
What could go wrong
This is an early, first-in-human trial with only 70 participants, so safety and effectiveness are not yet known. Side effects may occur, and the drug may not shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fort Wayne Medical Oncology and Hematology Inc.
Fort Wayne, Indiana, 46845, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
McGill University Health Centre
Montreal, Quebec, H4A 3J1, Canada
-
Providence Medical Foundation
Fullerton, California, 92835, United States
-
Sarah Cannon Research Institute
Denver, Colorado, 80218, United States
-
Sarah Cannon Research Institute-Tennessee
Nashville, Tennessee, 37203, United States
-
UCLA - JCCC Clinical Research Unit
Los Angeles, California, 90095, United States
-
University Health Network, Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
Washington University School of Medicine-Siteman Cancer Center
St Louis, Missouri, 63110, United States